Concepedia

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

Aiwu Ruth He, Roger B. Cohen, Crystal S. Denlinger, Ashwin R. Sama, Ariel E. Birnbaum, Jimmy J. Hwang, Takami Sato, Nancy Lewis, Michelle Mynderse, Michele Niland,

The Oncologist · 2019 · 60 citations · 40 references

DOIFull text

Open access

Abstract

Merestinib treatment in patients with advanced cancer demonstrated an acceptable safety profile and potential antitumor activity, supporting its future development in specific disease populations as a monotherapy and/or in combination with other therapies.

References

40

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 28.8K citations · Full text

, , +17

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.4K citations

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

, , +18

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig et al. · Cancer Discovery · 2015 · 782 citations · Full text